Wall Street ends flat after choppy session
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Stifel Cuts Price Target on Noble Energy (NBL) to $37 Following Israel Supreme Court Ruling
March 29, 2016 10:02 AM EDTStifel maintained a Buy rating on Noble Energy (NYSE: NBL), and cut the price target to $37.00 (from $40.00), following Supreme Court of Israel ruling that the government should provide stability assurances through a legal mechanism outside of the country's Natural Gas Regulatory Framework.
Analyst Michael... More
Rosenblatt Reiterates Buy on Pandora (P) as Tim Westergren Takes Over as CEO
March 29, 2016 9:51 AM EDTRosenblatt reiterated a Buy rating on Pandora (NYSE: P), with a price target of $15.00, following the company's announced management changes. The company announced that co-founder, Tim Westergren, is back in as CEO. Rosenblatt sees this move as very positive for the company on its fundamental... More
Piper Jaffray Remains Sidelined After Meeting with Pandora (P); Sees Changes as Positive
March 29, 2016 9:27 AM EDTPiper Jaffray remains Neutral on Pandora (NYSE: P) after meeting with management to discuss announced management changes. The appointment of the founder Tim Westergren to CEO signals that the company is not up for sale, helping the company lock-in major music labels into new direct licensing deals.... More
Wedbush Cuts Price Target on GameStop (GME) to $36 Following 4Q Results
March 28, 2016 8:11 AM EDTWedbush maintained an Outperform rating on GameStop (NYSE: GME), and cut the price target to $36.00 (from $38.00), following the company's 4Q report and guidance. Sales totaled $3.53 billion, compared with the consensus estimate of $3.57 billion. Non-GAAP EPS was $2.40, compared with the consensus estimate of $2.25.
Analyst... More
Leerink Affirms ACADIA Pharma (ACAD) at 'Outperform'; Pimavanserin Briefing Docs More Crticial than Expected
March 28, 2016 7:25 AM EDTLeerink affirms ACADIA Pharma (Nasdaq: ACAD) with an Outperform rating and $40 price target after the FDA Psychopharmacologic Drugs Advisory Committee released the pimavanserin briefing documents last Friday.
Analyst... More

